PTPI Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 jun 2024 @ 22:00):
Our systems believe the stock currently is undervalued by 0.05% compare to its pairs and should correct upwards.

Stats
Dagens volum	174 282
Gjennomsnittsvolum	432 150
Markedsverdi	3.20M
EPS	$-1.690 ( Q1 \| 2024-05-15 )
Neste inntjeningsdato	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0600 (Sector) 42.63 (Industry) 0
ATR14	$0.00300 (0.66%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX -1.40%

AKAN -3.75%

ALIM 0.54%

AMPH -0.87%

AMYT 0.00%

ANIP 0.94%

AQST 0.39%

ASRT -5.34%

ATNX 0.00%

AVDL -1.75%

AYTU 0.00%

BFRI -2.39%

BGXX -34.22%

CLVR -2.22%

COLL -0.74%

CPIX 0.66%

CRDL 1.00%

CRON -0.43%

CYTH 5.83%

DCPH 0.00%

DERM 9.73%

DRRX -5.49%

DVAX -1.23%

EGRX 11.55%

EMBC 0.32%

EMBCV -9.33%

EOLS -0.73%

ESPR -3.90%

EVOK 5.48%

FLGC 6.71%

FLXN 0.00%

GHSI -0.35%

HCM -1.83%

HROW -0.52%

HUGE -4.71%

IMCC 2.20%

INCR 2.03%

IRWD 5.16%

ITCI -3.51%

IXHL 10.53%

JUPW 11.76%

KALA 9.92%

KIN 0.11%

KMDA -1.78%

LNTH -1.25%

NBIX 2.50%

NEPT 0.00%

NLTX 1.45%

OGI -3.75%

OPTN -3.70%

ORGO 6.06%

PAHC -2.50%

PCRX 2.51%

PETQ -0.45%

PLXP 0.00%

PPD 0.00%

PROC -0.40%

PRPH -2.11%

PTPI 2.69%

RDHL -2.58%

RDUS 4.30%

REPH -0.48%

RGC -5.88%

RMTI 0.00%

SCTL 0.92%

SCYX -1.48%

SIGA 3.13%

SISI -13.33%

SNDL -1.04%

SNOA 1.05%

SSIC 1.03%

SUPN -0.45%

SXTC -2.24%

THTX 0.00%

TKNO -1.44%

TLGT -13.85%

TLRY -4.05%

TXMD -7.47%

TYHT -3.90%

UPC -1.97%

VTRS 1.43%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Bernstein Bruce	Buy	40 000	Stock Option (Right to Buy)
2023-12-21	Boctor Fady	Buy	54 533	Stock Option (Right to Buy)
2023-12-21	Boctor Fady	Buy	49 645	Common Stock
2023-12-21	Walker Wayne Remell	Buy	40 000	Stock Option (Right to Buy)
2023-12-21	Arnold Mitchell	Buy	20 000	Stock Option (Right to Buy)

INSIDER POWER
91.13
Last 73 transactions
Buy: 12 778 148 \| Sell: 66 349

Korrelasjon (AI algo v.1.1b): Undervalued: 0.05% $0.458 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.15 (neutral)

Kort: 0.04 (neutral)

Signal:(53.136) Neutral

Petros Pharmaceuticals, Korrelasjon

10 Mest positive korrelasjoner
BRZE	0.894
IDXX	0.885
GDYN	0.885
EZGO	0.883
NCNA	0.88
ATER	0.88
GSHD	0.879
ASUR	0.879
SHLS	0.879
CTSH	0.877

10 Mest negative korrelasjoner
LWAY	-0.926
CENX	-0.903
CURI	-0.892
SOHU	-0.884
VFF	-0.882
AMRK	-0.881
LABP	-0.878
QRHC	-0.878
NN	-0.877
SMTC	-0.875

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Petros Pharmaceuticals, Korrelasjon - Valuta/Råvare

-0.28
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.17
( neutral )

Petros Pharmaceuticals, Økonomi

Annual	2023
Omsetning:	$5.82M
Bruttogevinst:	$908 201 (15.60 %)
EPS:	$-3.75

FY	2023
Omsetning:	$5.82M
Bruttogevinst:	$908 201 (15.60 %)
EPS:	$-3.75

FY	2022
Omsetning:	$5.99M
Bruttogevinst:	$3.70M (61.79 %)
EPS:	$-13.06

FY	2021
Omsetning:	$7.81M
Bruttogevinst:	$6.21M (79.52 %)
EPS:	$-1 682.68

Financial Reports:

No articles found.

Petros Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Petros Pharmaceuticals,

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.